ApprovedFDA approval

Idvynso (doravirine and islatravir)

Merck Sharp & Dohme (MRK)

Marketer take

A two-drug switch regimen for virologically suppressed adults, competing with Dovato, Biktarvy and long-acting injectables in regimen-simplification conversations with HIV specialists.

Sponsor company
Merck Sharp & Dohme (MRK)
Indication
To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine
Therapeutic area
Infectious disease
Event
FDA approval
Date
Apr 20, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move